Clay Siegall and Seattle Genetics Lead the Battle on Cancer
Clay B. Siegall, Ph.D is the President, CEO and Chairman of the Board of Seattle Genetics. He co-founded the company in 1998. Dr. Siegall is a scientist by training, with a Bachelor of Science in Zoology from the University of Maryland and a Doctor of Philosophy (Ph.D.) in Genetics from The George Washington University. Clay Siegall received the Alumnus of the Year for Computer, Math and Natural Sciences at the University of Maryland.
As CEO of Seattle Genetics, Dr. Siegall has led the company to a leadership position in the marketplace by creating antibody-drug conjugates (ADCs) for cancer treatment. Dr. Siegall’s expertise and the innovative work of Seattle Genetics is well recognized. The company has formed a number of strategic licensing arrangements for its ADC technology with companies such as GlaxoSmithKline, Pfizer and Genentech (Roche). Dr. Siegall has also excelled as the leader of Seattle Genetics in capital raising activities. To date, the company has secured more than $675 million by way of private and public financings. Seattle Genetics executed an initial public offering in 2001.
Mr. Clay Siegall and Seattle Genetics are at the forefront of research into cancer treatments. One example is the work being done to have a new therapy brought to market for the treatment of Hodgkin lymphoma. In the summer of 2017, Seattle Genetics came forth with positive data resulting from their Phase III study of a new drug “cocktail” which drops the toxic bleomycin from the standard chemotherapy used to treat Hodgkin lymphoma.
Staying at the forefront of cancer research, and maintaining the effort to be a market leader, Dr. Siegall and Seattle Genetics recently negotiated the $614 million acquisition of the biotechnology company Cascadian Therapeutics. Just prior to the acquisition, Cascadian Therapeutics was in the midst of the decisive Phase II trials of a new breast cancer therapy known as “tucatinib.” Dr. Siegall states: “Tucatinib would complement our existing pipeline of targeted cancer therapies, provide a third late-stage opportunity for a commercial product in solid tumors and expand our global efforts in breast cancer.” (Endpoint News, January 31, 2018 https://endpts.com/restless-seattle-genetics-snaps-up-a-pivotal-stage-cancer-drug-with-614m-cascadian-buyout-pact/ )